Of course Bill Gates was involved.
Published 2023
The Gates Foundation, GMO Ticks, and a Mysterious Meat Allergy – A Story of Billions, Bugs, and Beef.
The number of Americans with Alpha-Gal Syndrome (AGS), a life-changing red meat allergy caused by tick bites, surged by 41.3% in 2021.
Why is this significant? Let's connect the dots.
1/ The Tick & The Grant: In that same year, 2021, the Bill & Melinda Gates Foundation awarded a $1.47M grant to Oxitec Ltd. Their mission? To genetically engineer the Rhipicephalus microplus tick—a known vector for AGS—with a "self-limiting gene."
2/ The "Solution": Oxitec's plan was to release these GMO male ticks to mate with wild females, aiming to crash the population. In June 2023, after reporting "high efficacy," Gates poured another $4.8 million into the project.
3/ The Pharmaceutical Stake: Gates holds significant investments in Pfizer, a major producer of doxycycline—the primary antibiotic used to treat tick-borne illnesses like Lyme disease. His foundation also funded Ceres Nanosciences, a Lyme disease diagnostics company.
4/ The Food Industry Pivot: Simultaneously, Gates is a massive investor in the alternative meat industry. He backs Beyond Meat, Impossible Foods, Upside Foods, and Good Meat—companies positioned to replace the very red meat that AGS renders inedible.
5/ A Controversial Playbook? This isn't the first time this pattern appears. Look at malaria, eradicated in the US for decades until recently:
2007: Gates makes malaria a top priority, investing hundreds of millions.
2018: A Gates-backed drug, Krintafel, becomes the first new malaria treatment in 60 years.
2020: Gates funds Oxitec (again) to release GMO mosquitoes in Florida and Texas.
2023: A Gates-backed malaria vaccine is stocked.
Weeks later, the CDC announces locally acquired malaria cases in... Florida and Texas. The CDC, which receives Gates funding, then recommends the very vaccine he backed.
The Question: Are we witnessing a devastating (coincidence) or a deeply concerning pattern? A problem emerges, a solution is funded, and the funder holds stakes in both the cause and the cure—while also investing in industries that benefit from the societal shift the problem creates.
There is no definitive evidence of causality yet. But the correlation and timing demand extreme scrutiny, total transparency, and absolute accountability.
The public is not a testing ground. Our health is not a portfolio.
